# SymBio Pharmaceuticals Limited: business model and financials

> Latest period: FY ending Dec 2025, consolidated, J-GAAP
> Unit: JPY millions
> Sources: 有価証券報告書－第21期(2025/01/01－2025/12/31) (S100XNE5)
> Page: https://vizora.meequs.com/en/company/symbio-pharmaceuticals
> Retrieved: 2026-09-30T22:33:42.767Z

## Company

SymBio Pharmaceuticals, founded in 2005, is a company in Pharmaceuticals listed on TSE Growth. It has 91 employees (consolidated).

| Field | Value |
| --- | ---: |
| Legal name | SymBio Pharmaceuticals Limited |
| Ticker | 4582 |
| Stock price | View on Yahoo Finance (https://finance.yahoo.co.jp/quote/4582.T) |
| Listing | TSE Growth |
| Head office | 東京都港区虎ノ門四丁目1番28号 |
| Representative (per filing) | 代表取締役社長兼CEO 吉田 文紀 |
| Founded | Mar 2005 |
| Share capital | ¥19.2B |
| Employees (consolidated) | 91 |
| Average salary (parent only) | ¥13.8M |
| Fiscal year end | December |
| Website | www.symbiopharma.com (https://www.symbiopharma.com/) |
| Corporate number | 1010401057034 |
| EDINET | E24682 |
| Industries (Vizora) | Pharmaceuticals |

> Profile source: annual securities report (S100XNE5, filed 2026-03-24). As of filing

## Five-axis industry profile

Primary industry: Pharmaceuticals (2025-12-31)

| Axis | Industry percentile | Peers |
| --- | ---: | ---: |
| Profitability | 2.3 | 22 |
| Efficiency | 4.7 | 32 |

Each axis is shown independently. Missing values are labeled unavailable; no combined score is calculated. Industry rank is not an investment recommendation.

## Key points (generated from figures)

- SymBio Pharmaceuticals brought in ¥1.31B in revenue.
- It lost about ¥340 for every ¥100 of sales at the operating level.
- Revenue changed -46.7% from the prior year.

## Key figures at a glance

| Metric | Value | Note |
| --- | ---: | ---: |
| Revenue | ¥1.31B |  |
| Operating income | -¥4.44B | Margin -339.6% |
| Net income | -¥4.78B | Margin -365.3% |
| Free cash flow | — |  |
| Employees (consolidated) | 91 |  |
| EPS | ¥-97.62 |  |
| Book value per share | ¥11.38 |  |
| Equity ratio | 23.9% |  |
| Shares outstanding | 59,567,080 |  |
| Treasury shares | 91,000 |  |
| Shareholders | 30,133 |  |
| Average salary (parent only) | ¥13.8M | Filing company only |
| Cash ratio | 74.6% | Cash ÷ revenue 220.5% |
| Vs. industry median margin | -346.8 pp | Pharmaceuticals |
| ROA | -108.1% | Derived from disclosed figures |

## Notable figures

- FY2025, operating loss is 340 per ¥100 of revenue
- FY2025, cash is 75% of total assets

## What changed in 5 years

Currency or consolidation scope differs; percentage changes are omitted.

| Metric | FY ending Dec 2020 | FY ending Dec 2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | ¥2987051000 | ¥1307648000 | — |
| Operating income | ¥-4506220000 | ¥-4440687000 | — |
| Operating margin | -150.9% | -339.6% | -188.7 pp |
| Employees | 127 people | 91 people | — |
| Cash and equivalents | ¥3848626000 | ¥2883503000 | — |

### Change in segment revenue mix

Span: FY ending Dec 2020 → FY ending Dec 2025. Stable segment keys are connected; unmatched shares are marked as new or reorganized. Shares use total segment revenue.

## Income statement（FY ending Dec 2025, consolidated, J-GAAP）

| Item | Amount (JPY mn) | % of revenue | Source |
| --- | ---: | ---: | ---: |
| Revenue | 1,308 | 100.0% | S100XNE5 |
| Cost of revenue | 360 | 27.6% | S100XNE5 |
| Gross profit | 947 | 72.4% | S100XNE5 |
| SG&A | 5,388 | 412.0% | S100XNE5 |
| Operating income | -4,441 | -339.6% | S100XNE5 |
| Ordinary income | -4,648 | -355.4% | S100XNE5 |
| Pretax income | -4,749 | -363.1% | S100XNE5 |
| Income tax | 28 | 2.1% | S100XNE5 |
| Net income | -4,776 | -365.3% | S100XNE5 |
| Net income attributable to owners | -4,776 | -365.3% | S100XNE5 |

## Per ¥100 of revenue（FY ending Dec 2025）

| Part | JPY |
| --- | ---: |
| Cost of revenue | 28 |
| SG&A | 412 |
| Operating income | -340 |
| (Ref.) Net income | -365 |

### Margin funnel

Gross margin 72.4% → Operating margin -339.6% → Net margin -365.3%
Derived from reported figures (DERIVED).

## Year over year（FY ending Dec 2024 → FY ending Dec 2025、JPY mn）

| Metric | Prior | Current | Change | % change |
| --- | ---: | ---: | ---: | ---: |
| Revenue | 2,453 | 1,308 | -1,145 | -46.7% |
| Gross profit | 1,873 | 947 | -926 | -49.4% |
| Operating income | -3,877 | -4,441 | -564 | — |
| Net income attributable to owners | -3,833 | -4,776 | -943 | — |
| Operating cash flow | -3,417 | -4,576 | -1,159 | — |

## History（JPY mn）

| Period | Revenue | Op. income | Op. margin | Net income | Op. CF | FCF | Source |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| FY ending Dec 2019 | 2,838 | -4,302 | -151.6% | -4,376 | -4,351 | -4,567 | S100L0KX |
| FY ending Dec 2020 | 2,987 | -4,506 | -150.9% | -4,090 | -4,122 | -4,271 | S100NPZC |
| FY ending Dec 2021 | 8,257 | 1,016 | 12.3% | 2,032 | 140 | 76 | S100NPZC |
| FY ending Dec 2022 | 10,008 | 1,964 | 19.6% | 1,179 | 1,614 | 1,567 | S100T3FG |
| FY ending Dec 2023 | 5,590 | -812 | -14.5% | -1,963 | -195 | -427 | S100VGDJ |
| FY ending Dec 2024 | 2,453 | -3,877 | -158.1% | -3,833 | -3,417 | -3,463 | S100XNE5 |
| FY ending Dec 2025 | 1,308 | -4,441 | -339.6% | -4,776 | -4,576 | — | S100XNE5 |

## People and productivity（FY ending Dec 2025, consolidated, J-GAAP）

| Metric | Value |
| --- | ---: |
| Revenue per employee (consolidated) | ¥14.4M |
| Operating income per employee (consolidated) | -¥48.8M |
| Net income per employee (consolidated) | -¥52.5M |

Employees, revenue and profit are consolidated. Average annual salary is a separate parent-company figure. Calculated from disclosed figures (DERIVED).

| History | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Employees (consolidated) | 141 | 122 | 109 | 108 | 91 |
| Average salary (parent company) | ¥11.9M | ¥12.1M | ¥13.3M | ¥13.2M | ¥13.8M |
| Average age (parent company) | 50.1 years | 52.1 years | 54.2 years | 56.0 years | 56.6 years |
| Average tenure (parent company) | 3.8 years | 4.7 years | 4.8 years | 5.3 years | 6.2 years |

Year over year: Employees (consolidated) -15.7% · Revenue (consolidated) -46.7%

## Revenue by geography

No geographic revenue breakdown was disclosed.

## Cash flow（FY ending Dec 2025, consolidated, J-GAAP）

| Item | Amount (JPY mn) | % of revenue | Source |
| --- | ---: | ---: | ---: |
| Operating cash flow | -4,576 | -349.9% | S100XNE5 |
| Investing cash flow | -76 | -5.8% | S100XNE5 |
| Financing cash flow | 3,622 | 277.0% | S100XNE5 |
| Share buyback | 0 | 0.0% | S100XNE5 |
| Change in cash | -1,080 | -82.6% | S100XNE5 |
| Cash and equivalents | 2,884 | 220.5% | S100XNE5 |

## Balance sheet

Figures are as of each fiscal year end. Derived values are marked as such in the source column. Lease liabilities are excluded from interest-bearing debt.

| Metric | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 | Source |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | 3,860 | 6,283 | 6,517 | 3,964 | 2,884 | S100NPZC, S100VGDJ, S100XNE5 |
| Total assets | 8,453 | 10,433 | 8,170 | 4,968 | 3,867 | S100NPZC, S100T3FG, S100VGDJ, S100XNE5 |
| Net assets | 6,746 | 8,506 | 7,210 | 4,198 | 1,272 | S100NPZC, S100VGDJ, S100XNE5 |
| Share capital | 17,158 | 17,548 | 17,953 | 18,337 | 19,244 | S100NPZC, S100T3FG, S100VGDJ, S100XNE5 |
| Property, plant and equipment | 84 | 69 | — | — | — | S100NPZC, S100T3FG |
| Intangible assets excluding goodwill | 259 | 222 | — | — | — | S100NPZC, S100T3FG |
| Current assets | 6,748 | 9,313 | 8,083 | 4,924 | 3,824 | S100NPZC, S100T3FG, S100VGDJ, S100XNE5 |
| Current liabilities | 1,518 | 1,924 | 957 | 766 | 1,290 | S100NPZC, S100T3FG, S100VGDJ, S100XNE5 |
| Total liabilities | 1,707 | 1,927 | 960 | 771 | 2,595 | S100NPZC, S100T3FG, S100VGDJ, S100XNE5 |
| Equity attributable to owners of parent | 6,227 | 8,094 | 6,939 | 3,873 | 911 | S100NPZC, S100T3FG, S100VGDJ, S100XNE5 |
| Retained earnings | -27,978 | -26,889 | -28,852 | -32,686 | -37,462 | S100NPZC, S100T3FG, S100VGDJ, S100XNE5 |
| Treasury stock | -86 | -88 | -89 | -90 | -90 | S100NPZC, S100T3FG, S100VGDJ, S100XNE5 |

### Assets and funding mix

| Assets | Share | Source |
| --- | ---: | ---: |
| Cash | 75% | S100XNE5 |
| Other assets | 25% | S100XNE5 |

| Funding source | Share | Source |
| --- | ---: | ---: |
| Other liabilities | 67% | S100XNE5 |
| Equity | 33% | S100XNE5 |

### Balance sheet history

| Metric | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Total assets | 8,453 | 10,433 | 8,170 | 4,968 | 3,867 |
| Equity | 6,746 | 8,506 | 7,210 | 4,198 | 1,272 |
| Interest-bearing debt | — | — | — | — | — |
| Cash | 3,860 | 6,283 | 6,517 | 3,964 | 2,884 |

### Cash quality

Net cash = cash − interest-bearing debt. Net debt ratio = (interest-bearing debt − cash) ÷ positive operating cash flow. Omit when debt components are incomplete; other ratios are derived from reported figures.

| Metric | Value |
| --- | ---: |
| Cash ratio (cash ÷ total assets) | 74.6% |
| Cash ÷ revenue | 220.5% |
| Net cash (cash − interest-bearing debt) | — |
| Net debt ÷ operating cash flow | — |
| Cash conversion (operating CF ÷ operating income) | — |
| Cash vs. profit gap | 201 JPY mn |
| Shareholder returns / net income | — |
| Shareholder returns / FCF | — |
| Shareholder payments — dividends / net income | — |
| Shareholder payments — dividends / FCF | — |
| CapEx intensity (capex ÷ revenue) | — |
| Investing CF relative to operating CF | — |

## ROA and ROE

ROE is decomposed into net margin × asset turnover × financial leverage. Leverage can raise ROE, so the ratio alone does not assess a company's condition. Ending balances are used without a prior year; total equity approximates parent equity when unavailable.

| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE | Sources |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| 2021 | 24.6% | 0.98× | 24.0% | 1.36× | 32.6% | S100NPZC |
| 2022 | 11.8% | 0.96× | 11.3% | 1.29× | 14.6% | S100T3FG |
| 2023 | — | —× | -21.1% | —× | — | S100VGDJ |
| 2024 | — | —× | -58.4% | —× | — | S100XNE5 |
| 2025 | — | —× | -108.1% | —× | — | S100XNE5 |

## Ownership

| Counterparty | Relation | Ratio | As of |
| --- | ---: | ---: | ---: |
| 吉田 文紀 | Major shareholder | 2.8% | 2025-12-31 |
| 楽天証券株式会社共有口 | Major shareholder | 2.4% | 2025-12-31 |
| 株式会社SBI証券 | Major shareholder | 2.3% | 2025-12-31 |
| MORGAN STANLEY ＆ CO. LLC（常任代理人 モルガン・スタンレーMUFG証券株式会社） | Major shareholder | 1.6% | 2025-12-31 |
| JPモルガン証券株式会社 | Major shareholder | 0.9% | 2025-12-31 |
| STATE STREET BANK AND TRUST COMPANY 510643（常任代理人 株式会社みずほ銀行決済営業部） | Major shareholder | 0.9% | 2025-12-31 |
| 陳元 | Major shareholder | 0.8% | 2025-12-31 |
| 村山 信也 | Major shareholder | 0.7% | 2025-12-31 |
| 木下 みどり | Major shareholder | 0.6% | 2025-12-31 |
| 日本証券金融株式会社 | Major shareholder | 0.5% | 2025-12-31 |

## Sources

| Document | ID | Published | URL |
| --- | ---: | ---: | ---: |
| 有価証券報告書－第21期(2025/01/01－2025/12/31) | S100XNE5 | 2026-03-24 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100XNE5,, |
| 有価証券報告書－第20期(2024/01/01－2024/12/31) | S100VGDJ | 2025-03-25 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100VGDJ,, |
| 有価証券報告書－第19期(2023/01/01－2023/12/31) | S100T3FG | 2024-03-22 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100T3FG,, |
| 訂正有価証券報告書－第18期(2022/01/01－2022/12/31) | S100QG6E | 2023-03-24 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100QG6E,, |
| 有価証券報告書－第17期(令和3年1月1日－令和3年12月31日) | S100NPZC | 2022-03-29 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100NPZC,, |
| 有価証券報告書－第16期(令和2年1月1日－令和2年12月31日) | S100L0KX | 2021-03-24 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100L0KX,, |

## Definitions

- Amounts are in millions of JPY (rounded). The period is stated in each table heading
- Operating margin = operating income ÷ revenue. Net income is attributable to owners of the parent when disclosed
- Free cash flow (FCF) = operating cash flow − capital expenditure
- ¥100 model = breakdown per ¥100 of revenue (rounded so parts sum to 100)
- Segment revenues include inter-segment sales and may not sum to consolidated revenue
- Source IDs are EDINET document IDs (docID). "算出" (derived) means computed from other disclosed values
- All figures are extracted mechanically from filings. AI-written text never generates figures
- Source: company filings submitted to EDINET (Financial Services Agency of Japan). Figures were extracted, edited and processed, and charts and text were created, by Vizora — not by the FSA (used under the Public Data License v1.0).